Alzheimer's disease
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
R van der Kant, LSB Goldstein… - Nature Reviews …, 2020 - nature.com
The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …
can revert or arrest progression of this disease. AD pathology is characterized by the …
CADD: predicting the deleteriousness of variants throughout the human genome
Abstract Combined Annotation-Dependent Depletion (CADD) is a widely used measure of
variant deleteriousness that can effectively prioritize causal variants in genetic analyses …
variant deleteriousness that can effectively prioritize causal variants in genetic analyses …
Dissecting the clinical heterogeneity of early-onset Alzheimer's disease
Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Early-onset Alzheimer's disease: what is missing in research?
Abstract Purpose of Review Early-onset Alzheimer's disease (EOAD), defined as
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …
Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the …
The Rotterdam Study: 2018 update on objectives, design and main results
MA Ikram, GGO Brusselle, SD Murad… - European journal of …, 2017 - Springer
Abstract The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …
Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia
WM van der Flier, ME de Vugt, EMA Smets, M Blom… - Nature aging, 2023 - nature.com
Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …
present. To address this challenge, we need a paradigm shift, where we focus on pre …
[HTML][HTML] Genetics of Alzheimer's disease: where we are, and where we are going
C Bellenguez, B Grenier-Boley, JC Lambert - Current opinion in …, 2020 - Elsevier
Highlights•More than 40 loci of interest have been associated with the risk of developing
AD.•Recent genetic data clearly implicate microglia as involved in the pathophysiological …
AD.•Recent genetic data clearly implicate microglia as involved in the pathophysiological …
Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets
A Sierksma, V Escott-Price, B De Strooper - Science, 2020 - science.org
To provide better prevention and treatment, we need to understand the environmental and
genetic risks of Alzheimer's disease (AD). However, the definition of AD has been …
genetic risks of Alzheimer's disease (AD). However, the definition of AD has been …
Long non-coding RNA (lncRNA) roles in cell biology, neurodevelopment and neurological disorders
V Aliperti, J Skonieczna, A Cerase - Non-coding RNA, 2021 - mdpi.com
Development is a complex process regulated both by genetic and epigenetic and
environmental clues. Recently, long non-coding RNAs (lncRNAs) have emerged as key …
environmental clues. Recently, long non-coding RNAs (lncRNAs) have emerged as key …